Valproic acid: conflicting evidence regarding the potential risk of neurodevelopmental disorders in children of men treated with it,
Ixchiq: restriction of its use to people at high risk of infection with the chikungunya virus,
Tavneos: enhanced liver function monitoring requirements and treatment discontinuation instructions to limit the known risk of serious liver injury
For the full text of the announcement click here.
For the text, as published on the website of the European Medicines Agency (EMA), please visit://www.ema.europa.eu/
